18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Ejnar Alex Kørner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks

doi:http://dx.doi.org/10.1002/ana.22068

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

Rik Vandenberghe, Koen Van Laere, Adrian Ivanoiu, Eric Salmon, Christine Bastin, Eric Triau, Steen Hasselbalch, Ian Law, Allan Andersen, Ejnar Alex Kørner, Lennart Minthon, Gaëtan Garraux, Natalie Nelissen, Guy Bormans, Chris Buckley, Rikard Owenius, Lennart Thurfjell, Gill Farrar, David J Brooks

IKM

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

598 Citationer (Scopus)

Abstract

The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.

Originalsprog	Engelsk
Tidsskrift	Annals of Neurology
Vol/bind	68
Udgave nummer	3
Sider (fra-til)	319-29
Antal sider	11
ISSN	0364-5134
DOI	https://doi.org/10.1002/ana.22068
Status	Udgivet - 2010

Adgang til dokumentet

http://dx.doi.org/10.1002/ana.22068

Citationsformater

Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Kørner, E. A., Minthon, L., Garraux, G., Nelissen, N., Bormans, G., Buckley, C., Owenius, R., Thurfjell, L., Farrar, G., & Brooks, D. J. (2010). 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology, 68(3), 319-29. https://doi.org/10.1002/ana.22068

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. / Vandenberghe, Rik; Van Laere, Koen; Ivanoiu, Adrian; Salmon, Eric; Bastin, Christine; Triau, Eric; Hasselbalch, Steen ; Law, Ian; Andersen, Allan; Kørner, Ejnar Alex; Minthon, Lennart; Garraux, Gaëtan; Nelissen, Natalie; Bormans, Guy; Buckley, Chris; Owenius, Rikard; Thurfjell, Lennart; Farrar, Gill; Brooks, David J.

I: Annals of Neurology, Bind 68, Nr. 3, 2010, s. 319-29.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Vandenberghe, R, Van Laere, K, Ivanoiu, A, Salmon, E, Bastin, C, Triau, E, Hasselbalch, S , Law, I, Andersen, A, Kørner, EA, Minthon, L, Garraux, G, Nelissen, N, Bormans, G, Buckley, C, Owenius, R, Thurfjell, L, Farrar, G & Brooks, DJ 2010, '18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial', Annals of Neurology, bind 68, nr. 3, s. 319-29. https://doi.org/10.1002/ana.22068

Vandenberghe, Rik ; Van Laere, Koen ; Ivanoiu, Adrian ; Salmon, Eric ; Bastin, Christine ; Triau, Eric ; Hasselbalch, Steen ; Law, Ian ; Andersen, Allan ; Kørner, Ejnar Alex ; Minthon, Lennart ; Garraux, Gaëtan ; Nelissen, Natalie ; Bormans, Guy ; Buckley, Chris ; Owenius, Rikard ; Thurfjell, Lennart ; Farrar, Gill ; Brooks, David J. / 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. I: Annals of Neurology. 2010 ; Bind 68, Nr. 3. s. 319-29.

@article{b35859d2bebe40c3b72db9e60c918c4e,

title = "18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial",

abstract = "The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.",

author = "Rik Vandenberghe and {Van Laere}, Koen and Adrian Ivanoiu and Eric Salmon and Christine Bastin and Eric Triau and Steen Hasselbalch and Ian Law and Allan Andersen and K{\o}rner, {Ejnar Alex} and Lennart Minthon and Ga{\"e}tan Garraux and Natalie Nelissen and Guy Bormans and Chris Buckley and Rikard Owenius and Lennart Thurfjell and Gill Farrar and Brooks, {David J}",

year = "2010",

doi = "http://dx.doi.org/10.1002/ana.22068",

language = "English",

volume = "68",

pages = "319--29",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "JohnWiley & Sons, Inc.",

number = "3",

}

TY - JOUR

T1 - 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

AU - Vandenberghe, Rik

AU - Van Laere, Koen

AU - Ivanoiu, Adrian

AU - Salmon, Eric

AU - Bastin, Christine

AU - Triau, Eric

AU - Hasselbalch, Steen

AU - Law, Ian

AU - Andersen, Allan

AU - Kørner, Ejnar Alex

AU - Minthon, Lennart

AU - Garraux, Gaëtan

AU - Nelissen, Natalie

AU - Bormans, Guy

AU - Buckley, Chris

AU - Owenius, Rikard

AU - Thurfjell, Lennart

AU - Farrar, Gill

AU - Brooks, David J

PY - 2010

Y1 - 2010

N2 - The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.

AB - The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.

U2 - http://dx.doi.org/10.1002/ana.22068

DO - http://dx.doi.org/10.1002/ana.22068

M3 - Journal article

VL - 68

SP - 319

EP - 329

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -